Patents Assigned to St. Jude Children's Research Hospital
  • Modified Sendai virus vaccine and imaging vector
    Patent number: 10329584
    Abstract: The present invention relates to a Sendai virus or recombinant Sendai virus vector. In particular the present invention provides methods, vectors, formulations, compositions, and kits for a modified Enders strain Sendai viral vector. An immunogenic vector can be used in any in vitro or in vivo system. Moreover, some embodiments include vectors for imaging virus growth, location and transmission.
    Type: Grant
    Filed: February 28, 2017
    Date of Patent: June 25, 2019
    Assignee: St. Jude Children's Research Hospital
    Inventors: Julia Lea Hurwitz, Toru Takimoto, Charles John Russell, Allen Portner, Karen Slobod
  • Methods for diagnosing and treating learning or mental disorders
    Patent number: 10308933
    Abstract: The present invention embraces methods for the diagnosis and treatment of learning or mental disorders such as schizophrenia using miR-25, miR-98, or miR-185.
    Type: Grant
    Filed: December 30, 2015
    Date of Patent: June 4, 2019
    Assignee: ST. JUDE CHILDREN'S RESEARCH HOSPITAL
    Inventors: Stanislav S. Zakharenko, Laurie R. Earls
  • PPAR AGONIST OR LXR AGONIST FOR USE IN THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS BY MODULATION OF LAP ACTIVITY
    Publication number: 20190145961
    Abstract: Compositions and methods are provided for modifying diagnosing and treating inflammatory disease. The methods and compositions can be used to ameliorate the effects of a deficiency in the LAP pathway for clearing dead cells. Thus, methods are further provided for modulating dead cell clearance using an effective amount of a pharmaceutical composition that targets the LAP pathway. Accordingly, pharmaceutical compositions that target the LAP pathway re provided herein. The methods and compositions described herein can be used to treat inflammatory disease, such as systemic lupus erythematosus (SLE).
    Type: Application
    Filed: April 20, 2017
    Publication date: May 16, 2019
    Applicants: Washington University, St. Jude Children's Research Hospital
    Inventors: Herbert W. Virgin, Douglas R. Green, Jennifer Martinez
  • Retinoid X receptor-gamma agonists and retinoid X receptor-alpha antagonists for treatment of cancer
    Patent number: 10286000
    Abstract: The invention is directed to the use of Retinoid X Receptor-gamma (RXR-gamma) agonists and Retinoid X Receptor-alpha (RXR-alpha) antagonists in treatment of cancer.
    Type: Grant
    Filed: October 24, 2014
    Date of Patent: May 14, 2019
    Assignee: St. Jude Children's Research Hospital, Inc.
    Inventors: Wai-Hang Leung, Wing Leung
  • Fusion Protein and Nucleic Acid Molecule for Light-Dependent Stress Granule Assembly
    Publication number: 20190127428
    Abstract: A nucleic acid molecule encoding a fusion protein composed of a plant cryptochrome at the amino terminus, and a GTPase-Activating Protein SH3 Domain-Binding Protein (G3BP) is provided for light-dependent, G3BP-mediated stress granule formation.
    Type: Application
    Filed: October 26, 2017
    Publication date: May 2, 2019
    Applicant: St. Jude Children's Research Hospital
    Inventors: Joseph Paul Taylor, Peipei Zhang
  • Aryl substituted aminomethyl spectinomycin analogs as antibacterial agents
    Patent number: 10266544
    Abstract: The invention relates to aryl substituted aminomethyl spectinomycin analogs, derivatives thereof, and related compounds, which are useful as anti-bacterial agents; methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating anti-bacterial infections using the compounds and compositions.
    Type: Grant
    Filed: September 29, 2014
    Date of Patent: April 23, 2019
    Assignee: St. Jude Children's Research Hospital, Inc.
    Inventors: Richard E. Lee, Samanthi L. Waidyarachchi, David F. Bruhn, Jiuyu Liu, Zhong Zheng, Jason W. Rosch
  • CLONING AND EXPRESSION SYSTEM FOR T-CELL RECEPTORS
    Publication number: 20190040381
    Abstract: The invention provides a method for rapid cloning of T-cell receptors (TCRs) (e.g., paired ?? and ?? TCR chains) and B-cell receptors (BCRs) (e.g. paired IgH or IgK or Ig?) from single cells by CDR3 substitution using single cell PCR products and Gibson Assembly techniques and a pre-generated TCR (or BCR) library in an expression vector.
    Type: Application
    Filed: December 2, 2016
    Publication date: February 7, 2019
    Applicant: St. Jude Children's Research Hospital, Inc.
    Inventors: Paul Thomas, Xizhi Guo, Pradyot Dash
  • Genetically Engineered Swine Influenza Virus And Uses Thereof
    Publication number: 20180369363
    Abstract: The present invention relates, in general, to attenuated swine influenza viruses having an impaired ability to antagonize the cellular interferon (IFN) response, and the use of such attenuated viruses in vaccine and pharmaceutical formulations. In particular the invention relates to attenuated swine influenza viruses having modifications to a swine NS1 gene that diminish or eliminate the ability of the NS1 gene product to antagonize the cellular IFN response. These viruses replicate in vivo, but demonstrate decreased replication, virulence and increased attenuation, and therefore are well suited for use in live virus vaccines, and pharmaceutical formulations.
    Type: Application
    Filed: September 10, 2018
    Publication date: December 27, 2018
    Applicants: Icahn School of Medicine at Mount Sinai, St. Jude Children's Research Hospital, The United States of America, As Represented by the Secretary of Agriculture
    Inventors: Peter Palese, Adolfo Garcia-Sastre, Richard J. Webby, Juergen A. Richt, Robert G. Webster, Kelly M. Lager
  • Chimeric receptors and uses thereof in immune therapy
    Patent number: 10144770
    Abstract: Disclosed herein are chimeric receptors comprising an extracellular domain with affinity and specific for the Fc portion of an immunoglobulin molecule (Ig) (e.g., an extracellular ligand-binding domain of F158 FCGR3A or V158 FCGR3A variant); a transmembrane domain (e.g., a transmembrane domain of CD8?); at least one co-stimulatory signaling domain (e.g., a co-stimulatory signaling domain of 4-1BB); and a cytoplasmic signaling domain comprising an immunoreceptor tyrosine-based activation motif (ITAM) (e.g., a cytoplasmic signaling domain of CD3?). Also provided herein are nucleic acids encoding such chimeric receptors and immune cells expressing the chimeric receptors. Such immune cells can be used to enhance antibody-dependent cell-mediated cytotoxicity and/or to enhance antibody-based immunotherapy, such as cancer immunotherapy.
    Type: Grant
    Filed: October 17, 2014
    Date of Patent: December 4, 2018
    Assignees: National University of Singapore, St. Jude Children's Research Hospital, Unum Therapeutics Inc.
    Inventors: Dario Campana, Ko Kudo, Charles Wilson, Kathleen McGinness
  • Methods of delivering factor VIII encoding nucleic acid sequences
    Patent number: 10124041
    Abstract: There is provided a nucleic acid molecule comprising a nucleotide sequence encoding a factor VIII protein, wherein a B domain portion of the factor VIII protein is encoded by a nucleotides sequence between 90 and 111 nucleotides in length and has an amino acid sequence that is at least 85% identical to SEQ ID NO: 4 which comprises six asparagine residues. Also provided is a factor VIII protein, a vector comprising the above nucleic acid molecule, a host cell, a transgenic animal, a method of treating Haemophilia A, and a method for the preparation of a parvoviral gene delivery vector.
    Type: Grant
    Filed: September 1, 2016
    Date of Patent: November 13, 2018
    Assignees: UCL BUSINESS PLC, ST. JUDE CHILDREN'S RESEARCH HOSPITAL
    Inventors: Amit Nathwani, Jenny McIntosh, Edward Tuddenham, Andrew Davidoff
  • METHOD FOR TREATING SCHIZOPHRENIA
    Publication number: 20180318331
    Abstract: The invention is directed to a method for treating the 22q11 deletion syndrome (22q11 DS) and schizophrenia (SCZ) by replenishment of decreased levels of miR-338-3p in thalamic neurons.
    Type: Application
    Filed: June 30, 2016
    Publication date: November 8, 2018
    Applicant: St. Jude Children's Research Hospital, Inc.
    Inventor: Stanislav S. ZAKHARENKO
  • Substituted urea depsipeptide analogs as activators of the CLPP endopeptidase
    Patent number: 10100090
    Abstract: In one aspect, the invention relates to substituted urea depsipeptide analogs, derivatives thereof, and related compounds, which are useful as activators with the ClpP endopeptidase; synthesis methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating infectious disease using the compounds and compositions. This abstract is intended as a scanning tool for purposes of search in the particular art and is not intended to be limiting of the present invention.
    Type: Grant
    Filed: March 4, 2016
    Date of Patent: October 16, 2018
    Assignee: St. Jude Children's Research Hospital
    Inventors: Richard E. Lee, Ying Zhao, Liu Jiuyu
  • Genetically engineered swine influenza virus and uses thereof
    Patent number: 10098945
    Abstract: The present invention relates, in general, to attenuated swine influenza viruses having an impaired ability to antagonize the cellular interferon (IFN) response, and the use of such attenuated viruses in vaccine and pharmaceutical formulations. In particular, the invention relates to attenuated swine influenza viruses having modifications to a swine NS1 gene that diminish or eliminate the ability of the NS1 gene product to antagonize the cellular IFN response. These viruses replicate in vivo, but demonstrate decreased replication, virulence and increased attenuation, and therefore are well suited for use in live virus vaccines, and pharmaceutical formulations.
    Type: Grant
    Filed: December 12, 2016
    Date of Patent: October 16, 2018
    Assignees: Icahn School of Medicine at Mount Sinai, St. Jude Children's Research Hospital, The United States of America, As Represented by the Secretary of Agriculture
    Inventors: Peter Palese, Adolfo Garcia-Sastre, Richard J. Webby, Juergen A. Richt, Robert G. Webster, Kelly M. Lager
  • METHODS AND COMPOSITIONS OF INHIBITING DCN1-UBC12 INTERACTION
    Publication number: 20180256558
    Abstract: In one aspect, the invention relates to substituted 1-phenyl-3-(piperidin-4-yl)urea analogs, derivatives thereof, and related compounds, which are useful as inhibitors of the DCN1-UBC12 interaction inhibitors of DCN1-mediated cullin-RING ligase activity, methods of making same, pharmaceutical compositions comprising same, methods of treating disorders using the disclosed compounds and compositions, methods of treating disorders associated with a DCN1-UBC12 interaction dysfunction, methods of treating disorders associated with a DCN1-mediated cullin-RING ligase activity dysfunction, methods of male contraception comprising the disclosed compounds and compositions, and kits comprising the disclosed compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Application
    Filed: September 19, 2016
    Publication date: September 13, 2018
    Applicants: Memorial Sloan Kettering Cancer Center, St. Jude Children's Research Hospital
    Inventors: Jaeki MIN, Daniel C. SCOTT, Deepak BHASIN, Brenda A. SCHULMAN, Bhuvanesh SINGH, Jared T. HAMMILL, R. Kiplin GUY
  • Treatments for gastrointestinal conditions
    Patent number: 10011589
    Abstract: Compounds for the treatment of bacterial and parasitic infections which are hybrid compounds of compounds having antibacterial or antiparasitic activity and compounds that decrease the absorption of the hybrid compound from the gastrointestinal tract. The compounds are preferably for use against C. difficile infections and comprise a hybrid molecule of an anti-C. difficile compound such as a nitroimidazole and a tetramic acid derivative.
    Type: Grant
    Filed: March 12, 2015
    Date of Patent: July 3, 2018
    Assignees: Board of Regents, The University of Texas System, St. Jude Children's Research Hospital, Inc.
    Inventors: Richard E. Lee, Philip T. Cherian, Julian G. Hurdle, Xiaoqian Wu
  • CHIMERIC RECEPTOR WITH NKG2D SPECIFICITY FOR USE IN CELL THERAPY AGAINST CANCER AND INFECTIOUS DISEASE
    Publication number: 20180135014
    Abstract: The invention provides a chimeric receptor comprising NKG2D, DAP10 and CD3 zeta. Also disclosed is a composition comprising this chimeric receptor and methods for making and using it to enhance the cytotoxicity and antitumor capacity of NK cells. The invention also encompasses methods for use of NKG2D-DAP10-CD3 zeta polypeptides, vectors and cells in methods for treating cancer and other proliferative disorders, as well as infectious diseases.
    Type: Application
    Filed: December 28, 2017
    Publication date: May 17, 2018
    Applicants: ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC., NATIONAL UNIVERSITY OF SINGAPORE
    Inventors: Dario Campana, Yu-Hsiang Chang
  • METHOD FOR ISOLATING AND PURIFYING ADENO-ASSOCIATED VIRUS PARTICLES USING SALT
    Publication number: 20180135024
    Abstract: Methods for isolating and optionally purifying AAV particles grown in cell cultures using a combination of lyotropic salts, removal of insoluble producer cell debris and DNA, and optional fractionation by hydrophobic interaction chromatography are described.
    Type: Application
    Filed: November 14, 2016
    Publication date: May 17, 2018
    Applicant: St. Jude Children's Research Hospital
    Inventors: David Joseph McNally, Bryan Andrew Piras, Michael Martin Meagher
  • CHIMERIC RECEPTOR WITH NKG2D SPECIFICITY FOR USE IN CELL THERAPY AGAINST CANCER AND INFECTIOUS DISEASE
    Publication number: 20180135013
    Abstract: The invention provides a chimeric receptor comprising NKG2D, DAP10 and CD3 zeta. Also disclosed is a composition comprising this chimeric receptor and methods for making and using it to enhance the cytotoxicity and antitumor capacity of NK cells. The invention also encompasses methods for use of NKG2D-DAP10-CD3 zeta polypeptides, vectors and cells in methods for treating cancer and other proliferative disorders, as well as infectious diseases.
    Type: Application
    Filed: December 28, 2017
    Publication date: May 17, 2018
    Applicants: ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC., NATIONAL UNIVERSITY OF SINGAPORE
    Inventors: Dario Campana, Yu-Hsiang Chang
  • CHIMERIC RECEPTOR WITH NKG2D SPECIFICITY FOR USE IN CELL THERAPY AGAINST CANCER AND INFECTIOUS DISEASE
    Publication number: 20180135015
    Abstract: The invention provides a chimeric receptor comprising NKG2D, DAP10 and CD3 zeta. Also disclosed is a composition comprising this chimeric receptor and methods for making and using it to enhance the cytotoxicity and antitumor capacity of NK cells. The invention also encompasses methods for use of NKG2D-DAP10-CD3 zeta polypeptides, vectors and cells in methods for treating cancer and other proliferative disorders, as well as infectious diseases.
    Type: Application
    Filed: December 28, 2017
    Publication date: May 17, 2018
    Applicants: ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC, NATIONAL UNIVERSITY OF SINGAPORE
    Inventors: Dario Campana, Yu-Hsiang Chang
  • CHIMERIC RECEPTOR WITH NKG2D SPECIFICITY FOR USE IN CELL THERAPY AGAINST CANCER AND INFECTIOUS DISEASE
    Publication number: 20180135016
    Abstract: The invention provides a chimeric receptor comprising NKG2D, DAP10 and CD3 zeta. Also disclosed is a composition comprising this chimeric receptor and methods for making and using it to enhance the cytotoxicity and antitumor capacity of NK cells. The invention also encompasses methods for use of NKG2D-DAP10-CD3 zeta polypeptides, vectors and cells in methods for treating cancer and other proliferative disorders, as well as infectious diseases.
    Type: Application
    Filed: December 28, 2017
    Publication date: May 17, 2018
    Applicants: ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC., NATIONAL UNIVERSITY OF SINGAPORE
    Inventors: Dario Campana, Yu-Hsiang Chang